Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Running, not enrolling · Phase 3

Conditions studied: Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer

In brief

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).

Key facts

Study ID
NCT06211036
Run by
Amgen
People needed
563
Starts
2024-06-05
Expected to finish
2028-09-30
Last updated by the study team
2025-12-17

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.